| Theme | Current Topics on Anorectal Disorders | |
|---|---|---|
| Title | Diagnosis and Therapy for Rectal Lymphomas | |
| Publish Date | 2005/09 | |
| Author | Masaaki Matsukawa | Department of Internal Medicine, Toyosu Hospital, Showa University |
| Author | Terushige Yamamoto | Department of Internal Medicine, Toyosu Hospital, Showa University |
| Author | Atsushi Sato | Department of Internal Medicine, Toyosu Hospital, Showa University |
| [ Summary ] | Lymphomas of the rectum are mostly a tumor of B-cell lymphocyte origin. Mucosa-associated lymphoid tissue type lymphoma (MALT lymphoma) accounts for 60 - 40 % of lymphomas in the large bowel. In radiological and endoscopic findings MALT lymphoma is seen as a submucosal tumor. Lymphomatous polypoid lesions of the intestine are shown as polyps in Mantle-cell lymphoma (MCL). Ulcerations in the lesions are recognized in high grade malignant lymphoma. CD 20 antigens are expressed in nearly all human B-cells and B-cell lymphoma cells. Rituximab is a chimeric anti-CD 20 monoclonal antibody with mouse variable and human constant regions. The overall response rates in relapsed indolent B-cell lymphoma and MCL were 61 % and 46 %. The results of Rituximab + CHOP therapy are the most effective in therapies for B-cell lymphoma. However, the results of therapy for MCL are less effective than for other B-cell lymphomas. | |